Bruna Flavia, Scodeller Pablo
Consejo Nacional de Investigaciones Científicas y Tecnicas, Universidad Nacional de Cuyo, Instituto de Medicina y Biología Experimental de Cuyo, Mendoza, Argentina.
Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Front Oncol. 2021 May 10;11:675664. doi: 10.3389/fonc.2021.675664. eCollection 2021.
In Oral Squamous Cell Carcinomas (OSCC), as in other solid tumors, stromal cells strongly support the spread and growth of the tumor. Macrophages in tumors (tumor-associated macrophages or "TAMs"), can swing between a pro-inflammatory and anti-tumorigenic (M1-like TAMs) state or an anti-inflammatory and pro-tumorigenic (M2-like TAMs) profile depending on the tumor microenvironment cues. Numerous clinical and preclinical studies have demonstrated the importance of macrophages in the prognosis of patients with different types of cancer. Here, our aim was to review the role of M2-like TAMs in the prognosis of patients with OSCC and provide a state of the art on strategies for depleting or reprogramming M2-like TAMs as a possible therapeutic solution for OSCC. The Clinical studies reviewed showed that higher density of CD163+ M2-like TAMs associated with worse survival and that CD206+ M2-TAMs are involved in OSCC progression through epidermal growth factor (EGF) secretion, underlining the important role of CD206 as a marker of OSCC progression and as a therapeutic target. Here, we provide the reader with the current tools, in preclinical and clinical stage, for depleting M2-like TAMs, re-educating them towards M1-like TAMs, and exploiting TAMs as drug delivery vectors.
与其他实体瘤一样,在口腔鳞状细胞癌(OSCC)中,基质细胞有力地支持肿瘤的扩散和生长。肿瘤中的巨噬细胞(肿瘤相关巨噬细胞或“TAM”),可根据肿瘤微环境线索,在促炎和抗肿瘤(M1样TAM)状态或抗炎和促肿瘤(M2样TAM)状态之间转变。大量临床和临床前研究已证明巨噬细胞在不同类型癌症患者预后中的重要性。在此,我们的目的是综述M2样TAM在OSCC患者预后中的作用,并提供关于消耗或重编程M2样TAM作为OSCC可能治疗方案的最新策略。所综述的临床研究表明,CD163 + M2样TAM密度较高与较差的生存率相关,且CD206 + M2 - TAM通过表皮生长因子(EGF)分泌参与OSCC进展,突显了CD206作为OSCC进展标志物和治疗靶点的重要作用。在此,我们为读者提供在临床前和临床阶段用于消耗M2样TAM、将它们重编程为M1样TAM以及利用TAM作为药物递送载体的当前工具。